Alnylam Pharmaceuticals (ALNY) Non Operating Investment Income (2014 - 2017)
Alnylam Pharmaceuticals' (ALNY) quarterly Non Operating Investment Income came in at -$345000.0 in Q2 2017, down 136.16% YoY from $954000.0 in Q2 2016, and up 77.73% on a QoQ basis from -$1.5 million in Q1 2017.
Alnylam Pharmaceuticals (ALNY) Non Operating Investment Income (2014 - 2017) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has 3 years of Non Operating Investment Income data on file, last reported at -$345000.0 in Q2 2017.
- Quarterly Non Operating Investment Income fell 136.16% year-over-year to -$345000.0 in Q2 2017, while the trailing twelve-month figure through Dec 2017 was -$1.9 million (down 127.15% YoY) and the FY2017 annual result came in at -$1.9 million, down 127.15% from the prior year.
- Non Operating Investment Income improved to -$345000.0 in Q2 2017, from -$1.5 million in the prior quarter.
- In the past five years, Non Operating Investment Income ranged from a high of $5.2 million in Q1 2016 to a low of -$1.5 million in Q1 2017.
- A 3-year average of $895500.0 and a median of $636500.0 in 2014 frame the typical range for Non Operating Investment Income.
- The widest YoY moves for Non Operating Investment Income: up 130.04% in 2017, down 136.16% in 2017.
- Tracing ALNY's Non Operating Investment Income over 3 years: stood at $1.5 million in 2014, then tumbled by 89.37% to $161000.0 in 2016, then sank by 314.29% to -$345000.0 in 2017.
- The last three Non Operating Investment Income figures came in at -$345000.0 (Q2 2017), -$1.5 million (Q1 2017), and $161000.0 (Q4 2016), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 36.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2017 | -345,000.00 |
| Jun 30, 2017 | -345,000.00 |
| Mar 31, 2017 | -1.55 Mn |
| Mar 31, 2017 | -1.55 Mn |
| Dec 31, 2016 | 161,000.00 |
| Dec 31, 2016 | 161,000.00 |
| Sep 30, 2016 | 706,000.00 |
| Sep 30, 2016 | 706,000.00 |
| Jun 30, 2016 | 954,000.00 |
| Jun 30, 2016 | 954,000.00 |
| Mar 31, 2016 | 5.16 Mn |
| Mar 31, 2016 | 5.16 Mn |
| Dec 31, 2014 | 1.51 Mn |
| Dec 31, 2014 | 1.51 Mn |
| Sep 30, 2014 | 567,000.00 |
| Sep 30, 2014 | 567,000.00 |